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Introduction
Data regarding the safety and efficacy of treatment
regimens for juvenile dermatomyositis (JDM) tends to be
from anecdotal, small, uncontrolled, non-randomized
case series.
Objectives
To find out the treatment regimen associated with the
lowest occurrence of flare and the lowest drug related
toxicity in juvenile dermatomyositis (JDM).
Methods
Children with newly diagnosed JDM were randomized
in an open fashion to receive: prednisone (PDN) versus
PDN plus methotrexate (MTX) versus PDN plus Cyclos-
porine A (CASA). Primary outcome measures after
6 months of treatment: response rate according to the
Paediatric Rheumatology International Trials Organisa-
tion (PRINTO) provisional definition of improvement.
Primary outcome measures after 24 months of treat-
ment: a) time to inactive disease; b) time to major thera-
peutic changes because of inefficacy/flare/adverse events;
time to flare.
Results
139 randomized patients were included in the efficacy
dataset. There were 82 females (59%) with a median age
at onset of 7.4 years (1st-3rd quartiles 4.4-10.6) and
a median disease duration of 2.8 months (1.3-5.3).
Frequency of response at 6 months was for 24/47 (51%)
for PDN, 32/46 (70%) for PDN+CSA and 32/46 (70%)
for PDN+MTX (p 0.032).
There was a statistically significant difference for inactive
disease/clinical remission between group 3 (PDN+MTX)
versus group 2 (PDN +CSA) and 1 (PDN) combined (Log-
Rank test p 0.021 and p 0.012, respectively) and in the
time to major therapeutic change (defined as the addition
of CSA or MTX or any other disease-modifying anti-
rheumatic drug) between group 1 (PDN) versus group
2 (PDN+CSA) and 3 (PDN+MTX) combined (p = 0.009).
No statistical significant differences in time to flare (Log-
rank test; p = 0.39). The safety analysis showed that group
2 (PDN+CSA) had greater number of adverse events (AE)
when compared to group 1 (PDN) and 3 (PDN+MTX)
(p = 0.005). Similarly there was a statistically significant
increase in the frequency of AE in group 2 (PDN+CSA)
when compared to Group 1 (PDN) and 3 (PDN+MTX)
in several systems (skin and subcutaneous tissues, gastro-
intestinal, and general disorders. Infections/infestations)
and others (hypertrichosis, hirsutism/hair growth, and
abdominal pain). There were no statistically significant
differences in serious AE among the 3 groups (p 0.17).
There were no deaths.
Conclusion
Combined therapy with PDN and either CSA or MTX
was more effective than with PDN alone. However the
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